Core Viewpoint - Iovance Biotherapeutics, Inc. is facing a class action lawsuit due to allegations of providing misleading statements about its growth potential and financial performance, leading to a significant drop in stock price [1][2]. Summary by Relevant Sections Allegations - The complaint claims that during the class period from May 9, 2024, to May 8, 2025, Iovance made overwhelmingly positive statements while concealing material adverse facts about its ability to generate demand for its treatments [1]. - The company announced reduced revenue guidance for fiscal year 2024, attributing this to maintenance issues, lower-than-expected Proleukin sales, and a variable pace in treatment initiation [1]. Financial Impact - Following the announcement of reduced guidance, Iovance's stock price plummeted from $3.17 per share on May 8, 2025, to $1.75 per share on May 9, 2025, marking a decline of approximately 44.795% in one day [1]. Next Steps for Shareholders - Shareholders who purchased Iovance shares during the specified class period are encouraged to register for the class action by July 14, 2025, to potentially become lead plaintiffs [2]. - Registered shareholders will receive updates through a portfolio monitoring software regarding the case's progress [2]. Law Firm's Commitment - The Gross Law Firm aims to protect investors' rights and seeks recovery for losses incurred due to misleading statements that artificially inflated Iovance's stock price [3].

Core Viewpoint - Iovance Biotherapeutics, Inc. is facing a class action lawsuit due to allegations of providing misleading statements about its growth potential while failing to meet revenue expectations, leading to a significant drop in stock price [1][3]. Summary by Relevant Sections Class Period and Allegations - The class period for the lawsuit is from May 9, 2024, to May 8, 2025 [3]. - Allegations include that Iovance made overwhelmingly positive statements while concealing material adverse facts about its ability to generate demand for its treatments [3]. Financial Performance and Stock Impact - On July 25, 2024, Iovance announced disappointing financial results for Q2 2024 and reduced its revenue guidance for the full fiscal year 2024 [3]. - Contributing factors to the lowered guidance included maintenance of the iCTC, lower than expected Proleukin sales, and a variable pace of treatment initiation at approved centers [3]. - Following the announcement, Iovance's stock price plummeted from $3.17 per share on May 8, 2025, to $1.75 per share on May 9, 2025, marking a decline of approximately 44.8% in one day [3]. Next Steps for Shareholders - Shareholders are encouraged to register for the class action by July 14, 2025, to potentially become lead plaintiffs [4]. - Registered shareholders will receive updates through a portfolio monitoring software regarding the case [4]. Law Firm Information - The Gross Law Firm is representing the shareholders and is recognized for its commitment to protecting investor rights against deceit and fraud [5].

Core Viewpoint - A lawsuit has been filed against Iovance Biotherapeutics, Inc. and certain senior executives for potential violations of federal securities laws, with claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 [1][2]. Company Overview - Iovance Biotherapeutics is a commercial-stage biopharmaceutical company focused on developing treatments for melanoma and other solid tumor cancers [3]. - The company launched its key melanoma treatment, Amtagvi, in February 2024, administered at authorized treatment centers (ATCs) [3]. Allegations and Issues - The lawsuit alleges that Iovance misrepresented the effectiveness of its ATCs as a driver of demand for Amtagvi, while in reality, these centers faced long timelines for patient treatment and high patient drop-off rates due to ineffective patient identification and selection [4]. - Following disappointing financial results for Q1 2025, Iovance revised its full-year 2025 revenue guidance, citing slow treatment timelines and high patient drop-off as contributing factors [5]. Stock Performance - On May 8, 2025, Iovance's stock price fell over 44%, dropping from $3.17 per share to $1.75 per share the following day, in response to the negative news regarding its financial performance and operational challenges [6].

Core Viewpoint - A class action lawsuit has been filed against Iovance Biotherapeutics, Inc. concerning allegations of securities fraud and unlawful business practices [2][4]. Financial Performance - Iovance reported a total product revenue of $49.3 million for Q1 2025, down from $73.7 million in the previous quarter, indicating a significant decline [4]. - The company revised its full fiscal year 2025 total product revenue guidance from a range of $450 million - $475 million to $250 million - $300 million, representing a reduction of over 40% at the midpoint [4]. - The updated revenue forecast reflects recent launch dynamics affecting Amtagvi, the company's lead product candidate, and considers growth trajectories and treatment timelines for new authorized treatment centers (ATCs) [4]. Stock Market Reaction - Following the financial results announcement, Iovance's stock price fell by $1.42 per share, or 44.79%, closing at $1.75 per share on May 9, 2025 [4].

NEW YORK, June 30, 2025 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) securities between May 9, 2024 and May 8, 2025, both dates inclusive (the "Class Period"), of the important July 14, 2025 lead plaintiff deadline.So What: If you purchased Iovance securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.What to do nex ...

Core Viewpoint - The Gross Law Firm is notifying shareholders of Iovance Biotherapeutics, Inc. regarding a class action lawsuit due to alleged misleading statements and a significant stock price decline following disappointing financial results [1][2]. Group 1: Allegations and Financial Performance - The class period for the allegations is from May 9, 2024, to May 8, 2025, during which Iovance allegedly provided overly positive statements while concealing material adverse facts about its growth potential [2]. - On July 25, 2024, Iovance announced its Q2 fiscal 2024 results and reduced its revenue guidance for the full fiscal year 2024, attributing this to maintenance issues, lower-than-expected Proleukin sales, and a variable pace of treatment initiation [2]. - Following the announcement, Iovance's stock price plummeted from $3.17 per share on May 8, 2025, to $1.75 per share on May 9, 2025, marking a decline of approximately 44.795% in one day [2]. Group 2: Next Steps for Shareholders - Shareholders are encouraged to register for the class action by July 14, 2025, to participate in the case without any cost or obligation [3]. - Registered shareholders will be enrolled in a portfolio monitoring system to receive updates on the case's progress [3]. Group 3: Law Firm's Mission - The Gross Law Firm aims to protect investors' rights against deceit and fraud, ensuring companies adhere to responsible business practices [4].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased securities of Iovance Biotherapeutics, Inc. during the specified Class Period of the upcoming lead plaintiff deadline on July 14, 2025, for a class action lawsuit [1][2] Group 1: Class Action Details - The class action lawsuit claims that during the Class Period, Iovance made false and misleading statements regarding the effectiveness of new Authorized Treatment Centers (ATCs) in treating patients with Amtagvi, leading to higher costs and lower revenue [3] - The lawsuit alleges that the delays in treatment timelines and ineffective patient identification by Iovance's sales team resulted in increased patient drop-offs, which negatively impacted the company's financial performance [3] Group 2: Legal Representation - Investors are encouraged to select qualified legal counsel with a proven track record in securities class actions, as many firms may not have the necessary experience or resources [4] - The Rosen Law Firm has a history of successful settlements in securities class actions, having recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [4]

Core Viewpoint - A lawsuit has been filed against Iovance Biotherapeutics, Inc. and certain senior executives for potential violations of federal securities laws, specifically related to the company's performance and treatment timelines for its melanoma drug Amtagvi [1][2]. Company Overview - Iovance Biotherapeutics is a commercial-stage biopharmaceutical company focused on developing treatments for melanoma and other solid tumor cancers [3]. Product Launch and Performance - Iovance launched its key melanoma treatment, Amtagvi, in February 2024, administering it at authorized treatment centers (ATCs) [3]. - The company has faced challenges with ATCs, including long timelines for patient treatment initiation and ineffective patient identification, leading to high patient drop-off rates [4]. Financial Impact - On May 8, 2025, Iovance reported disappointing financial results for the first quarter of 2025 and revised its full-year 2025 revenue guidance downward, citing slow treatment timelines and high patient drop-off rates as contributing factors [5]. - Following the announcement of poor financial results, Iovance's stock price fell over 44%, from $3.17 per share to $1.75 per share within a day [6].

Core Viewpoint - The departure of top-level management at Iovance Therapeutics has raised investor concerns, leading to a nearly 15% decline in the company's stock value during the week [1]. Management Changes - CFO Jean-Marc Bellemin resigned from his position, effective July 10, following a regulatory filing on June 13 [2][4]. - The resignation is occurring during a challenging period for the company, which is facing legal issues and a commercial setback for its flagship drug, Amtagvi [4]. Legal and Commercial Challenges - Iovance is currently under investigation by multiple law firms, which suggests that the company's legal troubles may be contributing to its management instability [2][4]. - The company has experienced a significant reduction in its product-revenue guidance for the year, despite some top-line growth attributed to Amtagvi, a melanoma drug [5]. Investment Outlook - While Iovance is facing significant challenges, Amtagvi still holds potential, indicating that the company may be worth monitoring for investors willing to take on higher risks [6].

Core Viewpoint - A class action securities lawsuit has been filed against Iovance Biotherapeutics, Inc. due to alleged securities fraud affecting investors between May 9, 2024, and May 8, 2025 [1][2] Group 1: Allegations and Financial Impact - The lawsuit claims that Iovance provided misleading positive statements while concealing material adverse facts about its growth potential, specifically its inability to generate demand for its treatments [2] - On July 25, 2024, Iovance announced a reduction in its revenue guidance for fiscal year 2024, attributing this to maintenance issues, lower-than-expected Proleukin sales, and the variable pace of treatment initiation at approved centers [2] - Following the announcement, Iovance's stock price plummeted from $3.17 per share on May 8, 2025, to $1.75 per share on May 9, 2025, marking a decline of approximately 44.8% in one day [2] Group 2: Legal Process and Participation - Investors who suffered losses during the specified period have until July 14, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require this role [3] - Class members may be entitled to compensation without any out-of-pocket costs or fees, indicating no financial obligation to participate [3] Group 3: Firm Background - Levi & Korsinsky has a history of securing significant settlements for shareholders and is recognized as one of the top securities litigation firms in the United States, with over 20 years of experience [4]